Spots Global Cancer Trial Database for refractory dedifferentiated liposarcoma
Every month we try and update this database with for refractory dedifferentiated liposarcoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma | NCT04668300 | Metastatic Angi... Metastatic Dedi... Metastatic Oste... Recurrent Angio... Recurrent Dedif... Recurrent Osteo... Refractory Dedi... Refractory Oste... | Durvalumab Oleclumab | 12 Years - | M.D. Anderson Cancer Center |